Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?

MEJ Lean and D Malkova

The aim of this article is to review the research into the main peripheral appetite signals altered in human obesity, together with their modifications after body weight loss with diet and exercise and after bariatric surgery, which may be relevant to strategies for obesity treatment. Body weight homeostasis involves the gut–brain axis, a complex and highly coordinated system of peripheral appetite hormones and centrally mediated neuronal regulation. The list of peripheral anorexigenic and orexigenic physiological factors in both animals and humans is intimidating and expanding, but anorexigenic glucagon-like peptide 1 (GLP-1), cholecystokinin (CCK), peptide YY (PYY) and orexigenic ghrelin from the gastrointestinal tract, pancreatic polypeptide (PP) from the pancreas and anorexigenic leptin from adiposites remain the most widely studied hormones. Homeostatic control of food intake occurs in humans, although its relative importance for eating behaviour is uncertain, compared with social and environmental influences. There are perturbations in the gut–brain axis in obese compared with lean individuals, as well as in weight-reduced obese individuals. Fasting and postprandial levels of gut hormones change when obese individuals lose weight, either with surgical or with dietary and/or exercise interventions. Diet-induced weight loss results in long-term changes in appetite gut hormones, postulated to favour increased appetite and weight regain while exercise programmes modify responses in a direction expected to enhance satiety and permit weight loss and/or maintenance. Sustained weight loss achieved by bariatric surgery may in part be mediated via favourable changes to gut hormones. Future work will be necessary to fully elucidate the role of each element of the axis, and whether modifying these signals can reduce the risk of obesity.

International Journal of Obesity (2016) 40, 622–632; doi:10.1038/ijo.2015.220

INTRODUCTION

Projections suggest that, by 2030, obesity prevalence may reach over 45% of the entire US population, and 48% in the United Kingdom.1 Behind this lies a progressive rise in body fat of over 45% of the entire US population, and 48% in the United Kingdom.2

The underlying processes do not emerge only when people reach an arbitrary BMI or waist cutoff for ‘obesity’, but exert causal influences from the earliest stages as body fat content begins to rise. The combined effects of physiological factors are usually only sufficient to generate weight gains of 0.5–1 kg year−1, which implies energy imbalances of around 10–20 kcal day−1, on average. This amount (< 1% of metabolic rate and energy requirements)10 is too small to detect by calorimetric methods, but is enough to cause weight gains of up to 40–50 kg over an adult life.11 These considerations indicate the significant difficulties that face any attempt to provide evidence for a quantitative mechanistic physiological explanation underlying obesity.

Over the past 20 years, there has been a glut of information on the physiological control of appetite in animal models; more than 30 gut hormones, neuropeptides and neurotransmitters are now known to affect appetite (Table 1). Many have been documented in both animals and humans, so might have roles in developing or treating obesity. Pharmacological agents directed at the compounds involved in physiological control of appetite have increasingly been investigated.12 However, even a drug that
| Hormone, neuropeptide, neurotransmitter | Primary source for appetite regulation | Proposed mechanism of action on appetite | Level of evidence |
|---------------------------------------|----------------------------------------|------------------------------------------|------------------|
| **Hormones**                          |                                        |                                          |                  |
| α-Melanocyte-stimulating hormone (α-MSH) | Hypothalamus                           | Stimulates hypothalamic MC3/4 receptors  | 2(ref. 119) (1 RCT) |
| Acetylcholine                          | CNS; PNS                               | Nicotinic acetylcholine receptor-mediated modulation of hypothalamic circuits regulating appetite and cortico-limbic-striatal reward circuits | 2(ref. 120) (3 RCTs) |
| Adrenocorticotropic hormone (ACTH)     | Hypothalamus                           | Stimulates hypothalamic MC3/4 receptors  | 2(ref. 119) (4 RCTs) |
| Amylin                                 | Pancreatic β cells (co-secreted with insulin) | Delays gastric emptying; targets the hindbrain and hypothalamus | 4(ref. 121) (5 RCTs) |
| Apolipoprotein A-IV                    | Intestinal epithelial cells            | Inhibits gastric motility, targets the hypothalamus | 2 (ref. 122) |
| Catecholamines (dopamine, epinephrine, norepinephrine) | Brain stem, adrenal gland               | Acute decrease in food intake          |                  |
| Caffeine                               | Hypothalamus                           | Modulates hypothalamic and hindbrain circuits | 1(ref. 124) |
| Cholecystokinin (CCK)                  | Duodenal/jejunal I cells               | Delays gastric emptying; targets the vagus nerve, hindbrain, and hypothalamus | 2(ref. 43) (37 RCTs) |
| Enterostatin                           | Exocrine pancreas                      | Inhibits fat intake, targets the hypothalamus | 2(ref. 125) (1 RCT) |
| Gastrin-releasing peptide (GRP)        | Gastric myenteric neurons              | Contributes to meal termination         | 2(ref. 126) (1 RCT) |
| Glucagon                               | Pancreatic α cells                     | Modulates gastric emptying and vagal tone | 4(ref. 127) (63 RCTs) |
| Glucagon-like peptide 1 (GLP-1)        | Intestinal L cells (co-secreted with PYY, OXM) | Decreases gastric emptying, promotes insulin secretion, suppresses glucagon secretion; targets the vagus nerve, hindbrain, and hypothalamus | 4(ref. 127) (136 RCTs) |
| Insulin                                | Pancreatic β cells                     | Targets the hypothalamus                |                  |
| Leptin                                 | White adipose tissue, stomach (secreted in proportion to adipose volume and total fat mass) | Signals the brainstem and arcuate nucleus of the hypothalamus when fat stores are low | 2(ref. 128) (68 RCTs) |
| Neuromedin B (NMB)                     | Gastric myenteric neurons              | Contributes to meal termination         | 0(ref. 131) |
| Neurotensin                            | Gastrointestinal enterendocrine cells  | Decrease in food intake is acute only   | 1(ref. 132) |
| Obestatin                              | Stomach, intestine                     | Decreases food intake, slows gastric emptying | 2(ref. 74) (2 RCTs) |
| Oxyntomodulin (OXM)                    | Intestinal L cells (co-secreted with GLP-1, PYY) | Delays gastric emptying; targets the hypothalamus | 2(ref. 133) (3 RCTs) |
| Oxytocin                               | Hypothalamus                           | Projections to caudal brainstem; inhibits gastric emptying | 2(ref. 134) (1 RCT) |
| Pancreatic polypeptide (PP)            | Pancreatic F cells                     | Delays gastric emptying; targets the vagus nerve and hindbrain | 2(ref. 135) (8 RCTs) |
| Peptide tyrosinotyrosine (PYY)         | Intestinal L cells (co-secreted with GLP-1, OXM) | Delays gastric emptying; targets the vagus nerve and hypothalamus | 2(ref. 136) (50 RCTs) |
| Serotonin                              | Midbrain, hindbrain                    | Targets hypothalamus                    | 4(ref. 136) (21 RCTs) |
| Vasactive intestinal polypeptide (VIP)  | Intestine, pancreas                    | Targets hypothalamus                    | 4(ref. 137) |
| **Neuropeptides**                      |                                        |                                          |                  |
| Agouti-related peptide (AgRP)          | Hypothalamus                           | MC3/4 receptor antagonist               | 2(ref. 138) (2 RCTs) |
| Endocannabinoids                       | Hypothalamus                           | Cannabinoid receptors widely distributed throughout the CNS | 2(ref. 139) (2 RCTs) |
| γ-aminobutyric acid (GABA)             | Ubiquitous in CNS                      | GABA/AgRP co-expressing neurons targeting the parabrachial nucleus of the hypothalamus | 6(ref. 140) |
| Galanin                                | Widely distributed in CNS, PNS and gut | Central stimulation of food intake mediated by galanin receptor-1; modulates hippocampal circuits | 2(ref. 141) (1 RCT) |
| Ghrelin                                | Gastric antrum and fundus              | Increases gastric emptying, decreases insulin secretion; targets the vagus nerve, hindbrain and hypothalamus | 2(ref. 142) (114 RCTs) |
| Glutamate                              | Ubiquitous in CNS                      | Stimulates AgRP/NPY-expressing neurons in the hypothalamus | 1(ref. 143) |
| Melanin-concentrating hormone (MCH)     | Hypothalamus                           | MCH neurons have widespread projections throughout the brain | 1(ref. 144) |
could completely reverse one major mechanism affecting appetite may not be expected to have an effect on body weight greater than perhaps 5–10%,5,13 when used as monotherapy, as other mechanisms remain active, and because beyond young childhood humans eat in response to a wide variety of physical or sensory cues and social triggers.14 The experience of eating for pleasure, akin to addictive behaviours (rather than appetite), is commonplace for most people even without obesity, and eating as a result of boredom is also very common. Social marketing by the food industry has exploited this to great advantage.

The gut–brain axis is the physiological driver of satiation in humans. Meal ingestion results in gastric distension and production of peptide hormones by enteroeendocrine cells, both of which can promote a feeling of fulness/satiety, and a desire to stop eating; this topic has been extensively reviewed elsewhere.15–17 Peptide hormones generated in the gastrointestinal (GI) tract and adipose tissue modulate appetite in both animal and human studies (Table 1). Peptides released, in response to ingested food, from multiple sites in the gut (including the stomach, proximal/distal small intestine, pancreas and colon), activate vagal afferent nerves that innervate brain regions involved in the immediate need for food intake.18,19 Peripheral signals from adipose tissue and the gut are integrated in the hypothalamus to influence short-term food intake and long-term energy balance; centrally released hormones and neurotransmitters also participate in appetite regulation.20–22 Cross-talk between peripheral satiety signals and hypothalamic and brainstem centres represents an integrative regulatory system for feeding, energy balance and body composition.

Homeostatic and hedonic systems in the brain also influence appetite and satiety. The physiologic need to eat during negative energy balance is a primitive survival function, mediated through the hindbrain and hypothalamus.2,5,23 In contrast, a desire to consume attractive foods arises from mesolimbic reward circuits and regions in the orbitofrontal cortex that regulates hedonic food intake based on the sensations of taste, smell, texture and sight.23–25 The hedonic systems are in constant interaction with homeostatic mechanisms and sensory attractiveness of foods can become dominant to contribute to weight gain and obesity. These mechanisms cannot be considered totally separate, indeed gut hormones such as ghrelin can alter the hedonic perceptions of food on presentation and consumption in response to negative energy balance, perhaps via the FTO gene expression or through dopaminergic mechanisms.26 A possible partial explanation for the recent obesity epidemic is that sensory stimulation related to food (that is, hedonic inputs) and overconsumption of palatable, energy-dense meals has increased markedly in society, whereas basic homeostatic satiety controls have remained stable.22,28

The concept of a physiological ‘set point’ whereby energy intake is automatically adjusted to maintain weight, or a specific component of body composition, is now relatively old, but begs questions about mechanisms. New evidence may suggest that there are structural changes in the hypothalamus, which could be responsible for resetting the putative set point in such a way that appetite will defend an increased body weight.29 The extent to which this might be relevant outside cases of hypothalamic obesity is uncertain, and there remains evidence that some people can adapt to live with a lower body weight after intentional weight loss.

This review aimed to provide a listing and concise summary of the hormones currently recognized to affect appetite, as a reference point for clinicians and researchers. It followed a structured approach to reach the totality of the published literature, to examine the currently available evidence on the biological regulation of appetite and the dysregulated gut- and adipose tissue-derived hormone signalling in overweight and obese individuals. It evaluates evidence on peripheral hormone responses to weight loss, achieved by either dietary and exercise interventions or surgical procedures, and aims to identify potential links between changes in hormone levels and obesity with a view to determine which changes are secondary and which may be primary and potentially causal.

### MATERIALS AND METHODS

Studies were identified by searching PubMed and Embase electronic databases for peer-reviewed, English-language publications between June 2008 and July 2013. Original studies were identified from the two databases by searching for the following terms in the title or abstract: ‘appetite’, ‘satiety’, ‘satiation’, ‘satiety response’ or ‘post-meal satiety’; in conjunction with: ‘obesity’, ‘body fat’, ‘weight gain’, ‘weight reduction’, ‘weight loss’, ‘waist circumference’ or ‘body mass index’; and together with: ‘hormone(s)’, ‘peptide(s)’, ‘glucagon-like peptide 1’, ‘peptide YY’, ‘leptin’, ‘ghrelin’, ‘pancreatic polypeptide’, ‘obestatin’ or ‘cholecystokinin’. Approximately 600 papers were identified and reviewed for relevance by two reviewers. Original studies were chosen for inclusion if they contained direct comparisons of hormonal satiety responses to a test meal in overweight or obese subjects versus lean controls. Studies of hormonal satiety responses before and post gastric bypass surgery or other weight loss interventions were included, as were neuroimaging studies that examined the effects of obesity on brain activation. The examination of bibliographies from published papers identified important sources published earlier than 2008.

There is a large body of literature on obesity and satiation in animals; articles were selected from the search results to illustrate

### Table 1. (Continued)

| Hormone, neuropeptide, neurotransmitter | Primary source for appetite regulation | Proposed mechanism of action on appetite | Level of evidence |
|----------------------------------------|---------------------------------------|-----------------------------------------|-------------------|
| Motilin (Mot)                           | Small intestine                       | Increases gastric motility, targets vagus nerve | 1(ref. 145) |
| Neuropeptide W (NPW)                   | Hypothalamus, stomach                 | Orexigenic: activation of melanin-concentrating hormone- and orexin-containing neurons | 2(ref. 146) |
| Neuropeptide Y (NPY)                   | Hypothalamus                          | Stimulates Y1 and Y5 receptors; modulates hypothalamic circuits | 3(ref. 141) |
| Orexin (hypocretin)                    | Central: Hypothalamus Periphery: enteric plexus, mucous and musculature in the gut | Stimulates gastric emptying | 4(ref. 147) |
| Visfatin                                | Visceral adipose tissue               | Potentially modulates hypothalamic circuits | 5(ref. 147) |

Abbreviations: CNS, central nervous system; MC, melanocortin; PNS, peripheral nervous system; RCT, randomized controlled trial. 0 = animal studies only; 1 = observational clinical studies; 2 = randomized controlled trials; 3 = systematic reviews of observational studies; 4 = systematic reviews of randomized controlled trials (with or without observational studies as well).
the hormones, peptides and neurotransmitters listed in Table 1, with additional focused searches conducted to confirm the level of evidence (where 0 = animal studies only, 1 = observational clinical studies, 2 = randomized controlled trials, 3 = systematic reviews of observational studies and 4 = systematic reviews of randomized controlled trials (with or without additional observational studies)). A number of peptides have not been included in the present review. For example, tumour necrosis factor was excluded because the subject population in most studies comprised patients with cancer or undergoing haemodialysis. Pro-opiomelanocortin was also excluded, as it is a precursor for adrenocorticotropic hormone and α-melanocyte-stimulating hormone, both of which are included in this review. Some additional peptides originally thought to influence eating habits no longer fit into either anorexigenic or orexigenic categories (for example, adiponectin has evidence for both; obestatin was originally thought to be anorexigenic, but more recent studies have not confirmed this and even suggested that the activity of obestatin may be dependent on ghrelin). When reviewing Table 1, note that preclinical models are not entirely analogous to obesity in humans, as stress-induced changes in feeding behaviour may result from different animal handling methods. Food intake by humans is, in large part, influenced by external factors and cognitive processes that are not operative in animals. Thus, although there is an ongoing contribution of animal studies towards better understanding of the mechanisms underlying obesity, this review focuses primarily on findings from studies in humans, with a view to establishing which alterations in mechanisms are secondary consequences of excess adiposity, which may be causal, and which may retain some potential for exploitation in obesity treatment.

Obesity and dysregulated appetite signalling

Findings from studies comparing the effects of obesity in humans on concentrations of peripheral appetite hormones in the fasting state or following a test meal and evidence on peripheral hormone responses to weight loss induced by dietary and/or exercise interventions or surgical interventions are reviewed. Emphasis has been placed on the hormones that have been the most widely studied (Table 1). In research of this kind, it is important to distinguish between dynamic effects arising from acute negative energy balance, and static effects that reflect a change in body composition. It is therefore important to include a period of weight stability after weight loss to remove the effects of acute energy imbalance, while recognizing that the components of energy balance may be different during weight stability (energy balance) after weight loss, for example, there may be altered macronutrient composition of the diet, or greater physical activity.

It is implicit in any analysis of endocrine functions that hormone actions must always reflect both circulating concentrations and also receptor number and sensitivity. In many cases, while it is relatively straightforward to measure plasma concentration, and sometimes circulating receptors, it is usually impossible to assess receptor or post-receptor functions in vivo. Sensitivity or resistance to a hormone action is invoked empirically when there are different responses to the same concentration.

Glucagon-like peptide 1. Glucagon-like peptide (GLP-1) (Table 1) is the product of post-translational processing of pro-glucagon in the gut and the brain. In the gut, GLP-1 is secreted primarily from enteroendocrine L cells located in the distal jejunum and ileum, and its release is stimulated by carbohydrate and fat intake. GLP-1 receptors are widely distributed in the brain, in peripheral organs such as the pancreatic islets, and in the whole GI tract. In the brain, GLP-1 receptors are found in areas that are implicated in the control of food intake and energy balance. GLP-1 has several other physiological functions: it acts as a strong incretin, that is, stimulates glucose-induced insulin release, and it inhibits glucagon release. In addition, GLP-1 activates the ‘leal brake’ by slowing the rate of gastric emptying, which slows nutrient absorption and contributes to the reduction of post-prandial glycaemia and enhanced satiety, and may explain nausea as a transient effect of GLP-1 receptor agonists. Both central and peripheral administration of GLP-1 have been shown to reduce food intake. Secretion of GLP-1 in response to food intake is biphasic: the early phase occurs within 10–20 min after food ingestion with a second peak at 30–60 min. After release, GLP-1 is rapidly inactivated and has a plasma half-life of less than 2 min.

Obesity has been associated with an attenuated postprandial GLP-1 response to test meals in a number of cross-sectional and longitudinal studies. Preprandial GLP-1 levels were similar for overweight/obese adults compared with normal-weight controls in a study conducted by Adam and Westerterp-Plantenga, but the postprandial GLP-1 response was significantly blunted in overweight/obese subjects 30 min after a test meal compared with control subjects. Another study revealed that while in normal-weight subjects GLP-1 levels increased 10 min after a standard liquid meal, in obese subjects GLP-1 levels declined markedly in the first 20 min (Figure 1). These data, however, contrast with a similar study by Bowen et al. in which postprandial GLP-1 levels were significantly greater in obese versus lean subjects after consumption of a buffet lunch. It should be noted that in this study the fasting concentrations of GLP-1 were also significantly higher in the obese individuals. Thus, the postprandial response may have been influenced by the fasting GLP-1 concentration rather than by obesity status.

Studies have examined the effects of dietary interventions for weight loss on GLP-1 levels. After a reduction of >8% of an initially obese body weight, with an 8-week low-energy diet (1000 kcal day−1) and a 2- to 3-week control diet standardization period, lower levels of fasting GLP-1 and greater appetite were observed compared with assessments in the same patients after a 6-month high monounsaturated fat dietary intervention which was accompanied by a modest (3.6 kg, 4.2%) weight regain. Another study monitored patients after an 8-week very-low-calorie diet (500–550 kcal day−1), followed by a 2-week weight stabilization period and a 52-week weight maintenance phase. After weight stabilization at week 10, patients had a mean weight loss of 14% of initial body weight. Patients regained some weight during the maintenance phase, remaining a mean of 8% below...
their initial body weight at week 62. Postprandial GLP-1 levels after 62 weeks were significantly lower than at baseline. The above studies support the view that modest diet-induced weight loss can result in long-term reductions in GLP-1, postulated to favour increased appetite and weight regain. This may at least in part explain why weight loss through caloric restriction is often so difficult to achieve and/or maintain for obese individuals.

Although caloric restriction-induced weight loss reduces GLP-1 levels, weight loss with exercise was reported to induce a response in the opposite direction. Martins et al.\textsuperscript{44} were the first to examine the effect of aerobic exercise training on fasting and postprandial levels of GLP-1 in obese individuals; a 12-week supervised exercise training programme (500 kcal of treadmill walking or running 5 days per week) had no impact of fasting GLP-1 concentration, but tended to increase its postprandial release.\textsuperscript{44} The tendency for a beneficial change in GLP-1 levels may explain why long-term exercise training typically permits body weight reduction and helps maintenance. The recent meta-analysis revealed a small mean effect for acute exercise to increase GLP-1 levels in normal-weight individuals.\textsuperscript{45} It remains unclear whether these findings apply to obese and overweight individuals.

Peptide YY. Peptide YY (PYY) is a satiety hormone whose anorexigenic effects are attributed to delayed gastric emptying (that is, the ileal brake) that is dose related and dependent on the amount of fat in the meal.\textsuperscript{46} PYY is co-secreted with GLP-1 by L cells in the lower intestine.\textsuperscript{47,48} Postprandial levels of PYY peak within 2 h of eating and are proportional to the size and type (fat > protein > carbohydrate) of the ingested meal.\textsuperscript{49,50} Fat intake is the strongest stimulant of PYY secretion, whereas carbohydrate intake has a limited effect in obese or non-obese individuals.\textsuperscript{51,52}

Several studies have documented the obesity-related attenuation of postprandial responses in PYY levels.\textsuperscript{53–55} For example, in one study, the PYY response in obese subjects was significantly lower than in normal-weight controls after each of six test meals of increasing caloric content (Figure 2). This attenuated response corresponded with significantly lower subjective ratings of fullness in obese subjects, beginning 30 min after the meal and persisting for 3 h.\textsuperscript{49} Zwirska-Korczala et al.\textsuperscript{55} also observed blunted postprandial PYY responses in obese and morbidly obese women compared with lean control subjects. Racial differences in PYY responses were examined in another study of obese and lean women.\textsuperscript{55} Significantly lower postprandial PYY levels were noted in obese black women compared with lean black women, lean white women or obese white women; unfortunately, given the known racial differences in body compositions, these authors did not report body fat content or any relationship between PYY levels and body composition.

Similar to the findings with GLP-1 levels, in obese subjects weight loss of > 8% from an 8-week low-energy diet followed by a 2- to 3-week weight stabilization period resulted in decreased levels of fasting PYY and increased hunger.\textsuperscript{52} Short-term diet-induced weight loss in another study also resulted in significant reductions in postprandial PYY levels and a significant increase in subjective appetite that persisted over a 12-month weight maintenance phase.\textsuperscript{43}

In contrast to dietary intervention studies, exercise studies conducted on overweight and obese individuals have reported increases or no change in PYY levels. An increase in fasting plasma PYY concentrations after 32 weeks of exercise training occurred in overweight male and female adolescents who experienced a significant decrease in body fat.\textsuperscript{56} Similarly, a significant increase in fasting PYY concentrations was reported in obese children who lost body weight following a 1-year diet and exercise intervention.\textsuperscript{57} One report noted a tendency for increased postprandial PYY concentrations in overweight and obese men and women after a 12-week exercise intervention.\textsuperscript{58} More recently, a study by Gueff et al.\textsuperscript{59} including overweight and obese men found that neither endurance nor resistance training significantly altered fasting and postprandial levels of PYY despite aerobic training being associated with increased satiety.\textsuperscript{58} Thus, evidence on the contribution of PYY to improved satiety during weight loss with exercise training remains controversial. The impact of a single exercise session on PYY response is more obvious, with most acute studies reporting a small increase in PYY levels immediately after exercise.\textsuperscript{43} This increase is consistent with the notion that acute increases in PYY can be expected to induce suppression of hunger and potentially diminish compensation for the expended energy. To date, no studies have been published investigating the impact of acute exercise on peptide YY responses in overweight and obese individuals.

Pancreatic polypeptide. Pancreatic polypeptide (PP) is produced under vagal control by the peripheral cells of the endocrine pancreatic islets, and to a lesser extent in the exocrine pancreas, colon, and rectum in response to a meal and to insulin-induced hypoglycemia (Table 1).\textsuperscript{11,59,60} In humans, administration of pharmacological doses of PP has been shown to decrease food intake.\textsuperscript{22} Furthermore, PP inhibits the gastric emptying rate, exocrine pancreatic secretion and gallbladder motility.\textsuperscript{60} Studies of PP in obese humans have demonstrated conflicting results. Some studies found no difference between lean and obese subjects,\textsuperscript{61} whereas other studies demonstrated lower fasting PP levels in obese subjects.\textsuperscript{55} If PP levels are decreased in obese subjects, then this could reflect a consequence of being overweight or, on the other hand, be a cause of being overweight as PP affects food intake.

Evidence of the effect of weight loss on PP concentrations in obese individuals is inconsistent.\textsuperscript{52,62–64} In one study, both postprandial PP concentrations and subjective ratings of hunger were increased after diet-induced weight loss and stabilization; the alterations persisted for at least 1 year after the initial weight loss.\textsuperscript{53} An increase in PP concentration following weight loss was also found in obese children.\textsuperscript{62} Thus, it could be assumed that the direction of change in PP following diet-induced weight loss is different from that reported in other gut hormones. However, fasting levels of PP, as with other anorexigenic gut hormones measured, were found to be reduced and appetite scores were increased in obese patients who experienced weight loss (in response to a short-term, low-energy diet) and weight stabilization compared with the same patients after they experienced some
Cholecystokinin. Cholecystokinin (CCK) is produced in duodenal and jejunal T cells and secreted in response to luminal nutrient (particularly fat) intake (Table 1).22,64,65 Structurally, CCK is related to gastrin and it exists in numerous molecular forms with different numbers of amino acids, for example, CCK-8, CCK-33 and CCK-39.66,67 The main effect of CCK on the GI system is to facilitate nutrient absorption, stimulate gall bladder contraction, enhance pancreatic enzyme secretion and slow gastric emptying.68–70 Delayed gastric emptying has been considered as a central mechanism by which CCK suppresses appetite.71 CCK is also present in different parts of the brain such as the amygdala, cortex, hippocampus, thalamus, hypothalamus, septum, dorsal hindbrain and basal ganglia, acting as a neurotransmitter.67,69,72 Compared with baseline measures, mean postprandial plasma concentrations of CCK were reduced in overweight and obese subjects who had lost a mean of 14% of their initial weight after an 8-week very-low-energy diet and a 2-week weight stabilization phase.73,74 Reductions in CCK levels persisted during the 1-year weight maintenance period. Similarly, rapid weight loss of approximately 15% of body weight in obese men who participated in a very-low-calorie diet intervention for 8 weeks and 1 week of weight stabilization resulted in significantly decreased postprandial CCK concentrations compared with baseline.75 These two studies suggest that CCK is reduced following rapid weight loss, a mechanism that might favour increased appetite and weight regain, and thus have a survival value. Both studies included a weight stabilization phase of 1–2 weeks; however, it is not certain whether this is sufficient for full metabolic adaptation to a neutral energy balance in overweight and obese subjects.

Evidence regarding the effect of exercise on CCK concentration, as with PP, is very limited. The recent study by Martins et al.76 reported that a 12-week exercise programme undertaken by overweight and obese sedentary individuals induced an average 3.5 kg weight loss but had no significant effect on either fasting or postprandial concentrations of CCK measured at least 48 h after the last exercise session to exclude the acute effects of exercise. The same study also found that exercise improved the ability to differentiate between preloads with different energy content. This implies that modifications in eating behaviour commonly seen with exercise are probably related to changes in levels and/or sensitivity of other appetite-regulating hormones and, as discussed in Supplementary information, alterations in neuronal responses to food. So far, data on the impact of acute exercise on CCK levels are available only from studies conducted on normal-weight individuals. These studies have reported increased CCK responses immediately after exercise and for up to 2 h.75,76 This significant increase in CCK concentrations observed in acute exercise studies is in line with suppressed hunger feelings reported during the immediate hours after exercise.77

Leptin. Leptin is a key adiposity hormone produced tonically by mainly white adipose tissue. Secretion increases as lipid content rises and it signals to receptors in the hypothalamus to reduce appetite and increase energy expenditure (Table 1).78 The main physiological role of leptin is probably through its suppression, during starvation and thinness, to increase appetite; when normal body fat content is restored, leptin is again secreted. Leptin also has a role in promoting fertility.79 Recent evidence suggests that leptin potentiates the effects of CCK on inhibition of food intake and that this interaction is disrupted in obesity.80 Humans with rare mutations in the leptin or leptin receptor gene suffer extreme early-onset obesity and have endocrine defects.81,82 Obesity and other consequences of leptin deficiency are corrected by long-term replacement therapy, so it appears certain that leptin has a key function in the regulation of energy balance in humans. However, in studies of adult humans, leptin concentrations correlated with total fat mass and appear to have little influence on energy intake. Leptin levels are decreased in patients with anorexia nervosa in a state of semi-starvation; during refeeding, levels increase in a BMI-dependent manner.83–85

In one study of lean and severely obese women, leptin levels were measured after a 12-h fast (baseline), and then over a 2-h period (measured at 0, 15, 30, 60, 90 and 120 min) following ingestion of a body weight-adjusted test meal (approximately one-quarter of the woman’s kcal needs; range, 576.1–803.8 kcal; 60% carbohydrate, 20% protein and 20% fat).84 Baseline leptin levels were significantly higher in the obese subjects at baseline. These levels decreased gradually over the first 90 min after the test meal and precipitously thereafter (at 120 min). This is in contrast to lean subjects in whom leptin levels remained relatively constant over the 2-h postprandial period. In another study, baseline leptin levels were also higher in obese subjects compared with lean controls; levels did not change in either group during the first 60 min following a test meal of up to 510 kcal.85 Higher circulating concentrations of baseline leptin in obese individuals, with greater fat masses, are not surprising. However, because leptin promotes satiety, these studies support the notion that obese individuals exhibit some type of central leptin resistance that disrupts the satiety response. In two studies, diet-induced weight loss of approximately 15% of initial body weight in obese subjects resulted in fasting leptin levels that were 35% lower than baseline and remained reduced compared with baseline for up to 1 year after weight loss and stabilization.43,86 The role of leptin in satiety was further examined in obese subjects who underwent a weight reduction programme and stabilization at 10% below their initial weight.87 Subjects received subcutaneous ‘replacement doses’ of recombinant human leptin or placebo twice daily for 5 weeks each. After ingesting a liquid-formula diet, subjects reported significantly higher levels of satiation on a visual analogue scale following leptin than following placebo injections. These studies further support the role of leptin in the regulation of satiety and suggest that leptin resistance might to some extent be overcome by massive weight loss. A role for physical activity, permitting transport of leptin into the brain, has also been proposed as a way to overcome leptin resistance.87

The notion that participation in exercise improves the activity of leptin is supported by evidence that exercise, when associated with mass loss, is followed by a significant reduction in fasting leptin concentrations and that this change increases rather than reduces subjective hunger measured in the fasted state.88 A recent study reported that exercise-induced weight loss leads not only to a reduction in fasting, but also in postprandial, concentrations of leptin.74 Another study involving a 12-week supervised exercise programme in sedentary overweight and obese individuals suggested that leptin concentrations measured both in the fasted state and after high- and low-energy test meals were significantly lower following exercise intervention, resulting in up to approximately 3.5 kg of weight loss.74 Despite this, the accuracy of compensation for previous energy intake was improved. Thus, reduced leptin concentrations after chronic exercise might indeed reflect improved leptin action.

Ghrelin. Ghrelin is a 28-amino acid peptide originally identified as the endogenous ligand of the growth hormone secretagogue receptor 1a (GHS-R1a).89 besides having growth hormone-
releasing activity, it is a potent orexigen with a fundamental influence on appetite and energy homeostasis regulation.7,18

Ghrelin is primarily expressed in the stomach as well as in the hypothalamus. The orexigenic functions of ghrelin have been attributed to total and acylated ghrelin, while unacylated form (> 90% of total ghrelin) has been considered as a non-functional peptide.90 Ghrelin concentration peaks in response to fasting and anticipation of the coming meal,91 and thus initiates and promotes eating (Table 1). Concentrations in normal-weight individuals exhibit a preprandial peak with a decline after eating.92 Working in opposition to satiety hormones, ghrelin increases the rate of gastric emptying93 and increases hunger.94 However, some recent data do not favour a role of peripheral ghrelin in the regulation of food intake.95,96 First, ghrelin infusion at both physiological and supraphysiological doses was found to have no effect on appetite or spontaneous meal request.95 In addition, it has been reported that food restriction-induced increases in appetite were not influenced by changes in plasma acylated ghrelin concentrations. At the same time over the past few years, effects of unacylated ghrelin on insulin sensitivity, metabolism, muscle regeneration and β-cell protection have been reported.97,98 Regardless of the current debate about the primary function of ghrelin, research investigating the role of this hormone in appetite regulation deserves discussion.

Fasting and postprandial plasma ghrelin levels were reported to be lower in obese than in normal-weight individuals (Figure 3).94 Little change from fasting levels was noted in obese subjects in other studies.39,50,55,84,85,99 One of these studies demonstrated a 30% reduction from preprandial ghrelin levels in lean women, beginning 30 min after a test meal, but no significant changes were noted in either obese or severely obese women.55 There may be nutrient-specific effects on ghrelin levels. Yang et al.50 found greater postprandial suppression of ghrelin in obese and lean subjects following a high-carbohydrate meal (88% carbohydrate, 8% protein and 4% fat) than after a high-fat meal (25% carbohydrate, 4% protein and 71% fat). However, compared with lean subjects, obese subjects demonstrated less suppression of ghrelin following either meal.

Thus, observations of the relationship between obesity and failure to suppress ghrelin levels after a meal are consistent across studies. The flattened hormone profiles around traditional mealtimes may be a factor in the continuous ‘grazing’ pattern reported in obese subjects.100,101

Diet-induced weight loss in obese subjects was accompanied by alterations in ghrelin levels in several studies. Compared with baseline measures, plasma ghrelin was increased by 17% in overweight and obese women who reduced their body weight by 4.5% at the completion of a 10-week weight loss intervention programme that included an energy-restricted diet of 40% carbohydrates, 30% fat and 30% protein.102 It should be noted that these results were obtained at the end of the acute intervention, and thus participants were presumably still in a state of negative energy balance, which may have confounded the results. In two other studies, short-term diet-induced weight loss in obese subjects resulted in an exaggerated pattern of postprandial changes in ghrelin levels compared with the pre-weight loss setting, with significantly greater levels persisting over weight maintenance/stabilization periods of 6 and 12 months.43,85 Repeated weight loss and regain may result in long-term alterations in ghrelin signalling. Among 159 weight-stable obese or overweight women, a history of intentional weight loss over the preceding 20 years, defined as episodes of intentionally losing at least 10 pounds, and frequency of intentional weight cycling were associated with higher fasting levels of ghrelin, in analyses adjusted for age, BMI and physical activity.103 This evidence raises the intriguing possibility that, as well as weight loss, weight cycling may promote an appetite-stimulating hormonal profile, further hindering weight maintenance. However, reaching this conclusion hinges on effective adjustment of the data for confounders, of which the most important is body composition; relatively small differences in body composition may introduce errors, and BMI is not sufficiently specific to avoid these errors.

The role of ghrelin in the control of appetite has been examined extensively in exercise studies. A recent meta-analysis reported that in normal-weight individuals, acute exercise suppresses acylated ghrelin levels,45 in line with a transient suppression of hunger in the hours immediately after exercise.104 However, chronic exercise resulting in significant weight loss was found to enhance fasting concentrations of total105 and acylated44 ghrelin in obese and overweight individuals. At the same time, increased suppression of postprandial acylated ghrelin was observed in one of the studies.44 This is in line with the observation that although medium-term exercise-induced weight loss increases both fasting hunger and hunger across the day, it also improves meal-induced satiety.106

In contrast to the above results, a study conducted in a group of morbidly obese men and women showed that fasting and meal related circulating ghrelin levels remained unchanged despite 5% weight loss induced by a 3-week integrated body weight reduction programme with exercise training.107 No impact of aerobic training on circulating acylated ghrelin levels was found in a study conducted on overweight and obese men58 and overweight children.108 Differences in fat mass loss, volume and duration of exercise interventions, and inclusion of different genders are likely to be factors contributing to the discrepancy. In addition, changes in ghrelin concentration with exercise may be also dependent on extent and direction of change in levels of other potential appetite regulators, such as a leptin, insulin and probably PYY.109,110

Effect of corticosteroids on gut peptides

Elevated corticosteroid status provides a useful model for some types of obesity. Weight gain varies widely in human clinical studies, depending on dose/circulating concentration and on individual factors. Alterations in the hypothalamic–pituitary–adrenal axis have been demonstrated in obesity.111 Weight gain is a feature of Cushing’s syndrome and a common side effect of

Figure 3. Ghrelin responses to a test meal in 10 normal-weight and 13 severely obese women. Ghrelin levels were significantly higher. * (P ≤ 0.05) in normal-weight women at baseline (P = 0.001) and at 15 (P = 0.001), 60 (P = 0.032) and 120 (P = 0.044) min postprandially.104 Reproduced with permission.
glucocorticoid therapy. A systematic review has suggested an average weight gain of 2 kg, but the stringent inclusion criteria of that review resulted in only one RCT paper being included. It is surprising that weight change with corticosteroids, which can often be large, has not been better documented. Therapeutic doses of glucocorticoids were shown to increase food intake in healthy male volunteers (N = 10). Vicennati et al. reported weight gain and the development of obesity in women (N = 14) after a significant stressful event; these changes were manifested via a hyperactive adrenal cortex. In another study, stress-related cortisol secretion was positively correlated with BMI, waist-to-hip ratio and sagittal reumbent trunk diameter in a population of 51-year-old men (N = 284). In a study examining the effects of methodology on gut hormone levels in 10 normal-weight men, the temporal plasma PYY concentration profile was altered by study-induced stress, and the PYY area under the curve was positively correlated with the cortisol area under the curve. In 33 young adults, serum ghrelin exhibited a strong inverse association with serum cortisol during 12–33 young adults, serum ghrelin concentration was generally lower in young adults than in healthy male volunteers; thus, the authors concluded that weight gain observed with glucocorticoid treatment may not be mediated by ghrelin.

CONCLUSIONS
Obesity in humans arises from excess energy consumption relative to expenditure over long periods, with secondary hyperphagia that opposes weight loss. Although adult eating patterns are influenced substantially by social, cultural and commercial factors, food intake is also regulated by a complex and inter-connected array of peripheral hormonal signals, originating in the gut and adipose tissue in humans. The list of peripheral hormones that regulate appetite and food intake is long and growing. Studies related to gut and adipose tissue hormones and obesity suggest that obesity is associated with a blunted postprandial response of satiety factors such as GLP-1 and PYY, CCK and reduced postprandial suppression of orexigenic ghrelin, and some type of central leptin resistance. Caloric restriction-induced weight loss causes persistent changes in peripheral hormones that tend to increase appetite and promote weight regain, while bariatric surgery and exercise programmes modify responses in a direction expected to enhance satiety and permit weight loss and/or maintenance. This suggestive causal relationship between weight loss following caloric restriction, exercise and gastric bypass surgery (see Supplementary information) and peripheral hormone alterations was not found in all studies.

Research into the regulation of appetite and body weight has seen a dramatic increase in the last 20–30 years, as the obesity epidemic has emerged, and the recognition of adipose tissue as an active endocrine organ is one of the most remarkable paradigm shifts of the last 100 years. Future research must focus clearly between causal factors in the disease process of obesity and physiological changes and adaptations to the state of obesity. Simply measuring differences between obese and non-obese individuals can be misleading. To unravel and begin to correct the causes of the obesity epidemic there is a need for more studies on longitudinal changes, and on the interactions between potential factors in this complex, multifactorial disease. The principle drivers of the epidemic seem clearly to be social, with both reduced physical activity and greater provision and promotion of energy-dense foods contributing. It is now incontrovertible that endocrine factors are playing a part, but the extent to which their roles are causal needs definition. The extent to which interventions via endocrine systems can ameliorate the situation for obese people will be defined by ongoing and planned clinical research, but modern analogue therapies appear to offer remarkably low-risk and effective treatments when used in conjunction with nutritionally-sound evidence-based diet and exercise regimens.

Taken together, the research findings presented in this review are building a foundation for the identification of targets for lifestyle and therapeutic interventions in obesity. Ongoing research will further our understanding of the effects of obesity on body weight homeostasis and potentially enable us to exploit, at least for some obese individuals, the effects of gut and adipose tissue hormones involved in the regulation of appetite.

CONFLICT OF INTEREST
ML has received institutional research grants and has received fees for work on advisory boards for Novo Nordisk A/S.

ACKNOWLEDGEMENTS
Editorial and medical writing support was provided by Amanda Sheldon, PhD; Marc van Bekkum, MSc; and Roderick Saye, BSc, MBA at CHC Group, who conducted the literature searches and primary content analyses, under the direction and supervision of ML. This support was funded by Novo Nordisk A/S. ML and DM provided extensive comments throughout the process and carefully reviewed and approved the final version of the manuscript for submission.

REFERENCES
1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815–825.
2. Atkinson RL. Current status of the field of obesity. Trends Endocrinol Metab 2014; 25: 283–284.
3. Wassoupolos A, Combet E, Lean ME. Changing distributions of body size and adiposity with age. Int J Obes 2013; 38: 857–864.
4. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1–7.
5. Gibson CD, Carnell S, Ochner CN, Geliebter A. Neuroimaging, gut peptides and obesity: novel studies of the neurobiology of appetite. J Neuroendocrinol 2010; 22: 833–845.
6. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Ann Rev Physiol 2008; 70: 239–255.
7. Stima D, Klobucar Majanovic S, Franjac N. Stomach–key player in the regulation of metabolism. Dig Dis 2014; 32: 192–201.
8. Fatourea C, Seaone LM, Casanueva FF. The brain-stomach connection. Front Horm Res 2014; 42: 83–92.
9. Grimm ER, Steinnie NL. Genetics of eating behavior: established and emerging concepts. Nutr Rev 2011; 69: 52–60.
10. Redman LM, Kraus WE, Bhatkar M, Das SK, Racette SB, Martin CK et al. Energy requirements in nonobese men and women: results from CALERIE. Am J Clin Nutr 2014; 99: 71–78.
11. Garrod JS. Obesity. Encyclopaedia of Life Sciences. John Wiley & Sons: Malden, MA, USA, 2001.
12. Rodgers RJ, Tschock MH, Widing JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5: 621–626.
13. Colon-Gonzalez F, Kim GW, Lin JE, Valentino MA. Waldmann SA. Obesity pharmacotherapy: what is next? Mol Aspects Med 2013; 34: 71–83.
14. Lowe MR, Butryn ML. Hedonic hunger: a new dimension of appetite? Front Psychiatry 2007; 91: 432–439.
15. Delbenne N, Blundell J, Brouns F, Cunningham K, De Graaf R, Erkner A et al. Gastrointestinal targets of appetite regulation in humans. Obes Rev 2010; 11: 234–250.
16. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13–23.
17. Field BC. Neuroendocrinology of obesity. Br Med Bull 2014; 109: 73–82.
18. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 2004; 55: 137–154.
19. Schwartz GJ. Integrative capacity of the caudal brainstem in the control of food intake. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1275–1280.
20. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Physiol Rev 2010; 90: 1187–1209.
21. Suzuki K, Simpson KA, Mininon JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010; 57: 359–372.
22. Yu JH, Kim MS. Molecular mechanisms of appetite regulation. Diabetes Metab J 2012; 36: 391–398.
Karlsson J, Persson LO, Sjostrom L, Sullivan M. Psychometric properties and reliability of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord 2000; 24: 1715–1725.

Zunker C, Karr T, Saunders R, Mitchell JE. Eating behaviors post-bariatric surgery: a qualitative study of grazing. Obes Surg 2012; 22: 1225–1231.

Ara SM, Vaishnav U, Pugliisi M, Lofgren IE, Wood RJ, Volek JS et al. Macronutrient composition and increased physical activity modulate plasma adipokines and appetite hormones during a weight loss intervention. J Womens Health 2010; 19: 139–145.

Hooper LE, Foster-Schubert KE, Weige DS, Sorensen B, Ulrich CM, McTiernan A. Frequent intentional weight loss is associated with higher ghrelin and lower glucose and androgen levels in postmenopausal women. Nutr Res 2010; 30: 163–170.

Martins C, Morgan LM, Bloom SR, Robertson MD. Effects of exercise on gut hormones, energy intake and appetite. J Endocrinol 2007; 193: 251–258.

Foster-Schubert KE, McTiernan A, Frayo RS, Schwartz RS, Rajan KB, Yasi Y et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab 2005; 90: 820–825.

King NA, Caudwell JP, Hopkins M, Stubbs JR, Naslund E, Blundell JE. Dual-process action of exercise on appetite control: increase in orexigenic drive but improvement in meal-induced satiety. Am J Clin Nutr 2009; 90: 921–927.

Morpurgo PS, Resnik M, Agosti F, Cappellini V, Sartorio A, Spada A. Ghrelin secretion in severely obese subjects before and after a 3-week integrated body mass reduction program. J Endocrinol Invest 2003; 26: 723–727.

Kim HJ, Lee S, Kim TW, Kim HH, Jeon TY, Yoon YS et al. Effects of exercise-induced weight loss on acylated and unacylated ghrelin in overweight children. J Endocrinol (Oxf) 2008; 68: 416–422.

Konturek SJ, Pepera J, Zabielski K, Konturek PC, Pawlik T, Szlachcic A et al. Brain-gut axis in pancreatic secretion and appetite control. J Pharmacol Pharmacol 2003; 54: 293–317.

Mason C, Xiao I, Imayama I, Duggan CR, Campbell KL, Kong A et al. The effects of separate and combined dietary weight loss and exercise on fasting ghrelin concentrations in overweight and obese women: a randomized controlled trial. Clin Endocrinol (Oxf) 2015; 82: 369–376.

Pasqualli R, Cantobelli S, Casminini F, Capelli M, Bortoluzzi L, Flamia R et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993; 77: 341–346.

Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100: 395–404.

Tataranni AP, Larson DE, Snidker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996; 271: E131–E132.

Vicennati V, Pasqui F, Cavazza C, Pagotto U, Pasqualli R. Stress-related development of obesity and cortisol in women. Obesity 2009; 17: 1678–1683.

Rosmond R, Dallman MF, Bjontorp P. Stress-induced cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853–1859.

Chandarana K, Drew ME, Emmanuel J, Karra E, Gelegen C, Chan P et al. Subject standardization, acclimatization, and sample processing affect gut hormone levels and appetite in humans. Gastroenterology 2009; 136: 2115–2126.

Espelund U, Hansen TK, Hjollund K, Beck-Nielsen H, Clausen JT, Hansen BS et al. Fasting causes a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab 2005; 90: 741–746.

Otto B, Tischop M, Heldwein W, Pfeiffer AF, Diederich S. Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol 2004; 151: 113–117.

Hallschmid M, Benedict C, Born J, Fehm HL, Kenn W. Manipulating central nervous systems mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 2004; 83: 55–64.

Mittermair R, Keller C, Geibel J. Intragastric injection of butyline toxin A for the treatment of obesity. Obes Surg 2007; 17: 732–736.

Duncan KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Am J Health Syst Pharm 2010; 67: 1226–1231.

Culnan DM, Cooney RN, Stanley B, Lynch CJ. Apolipoprotein A-IV, a putative antiatherogenic factor, rises after gastric bypass. J Clin Endocrinol Metab 1996; 81: 5384–5392.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–660.

Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut 2006; 55: 351–355.

Cummins DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger measures in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004; 287: E297–E304.

Cummins DE, Purnell JQ, Frayo RS, Schmidova K, Wisse B, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714–1719.

Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006; 55: 327–333.

Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.

Lipp F, Erdmann J, Steiger A, Lichter N, Czogalla-Peter C, Bidlingmaier M et al. Low-dose ghrelin infusion–evidence against a hormonal role in food intake. Regul Pept 2012; 174: 26–31.

Deighton K, Battenham RL, Stensel DJ. Appetite and gut peptide responses to exercise and calorie restriction. The effect of moderate energy deficits. Appetite 2014; 81: 52–59.

Delhanty PJ, Negers SJ, van der Lely AJ. Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do? Front Horm Res 2014; 42: 163–174.

Callaghan B, Furness JB. Novel and conventional receptors for ghrelin, desacetylghrelin, and pharmacologically related compounds. Pharmacol Rev 2014; 66: 984–1003.

English PJ, Ghatie MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984.
Supplementary Information accompanies this paper on International Journal of Obesity website (http://www.nature.com/ijo)